Clinical trial
TNF-Alpha Inhibition for Treatment of Alzheimer's Disease
NCT00203320 · Tobinick, Edward Lewis, M.D., Other · Completed
Key facts
| NCT number | NCT00203320 |
|---|---|
| Title | TNF-Alpha Inhibition for Treatment of Alzheimer's Disease |
| Official title | Etanercept for Alzheimer's-Type Memory Loss Pilot Study II |
| Lead sponsor | Tobinick, Edward Lewis, M.D., Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | etanercept given by perispinal administration |
| Enrollment | 30 |
| Start date | Apr 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Apr 24, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: